Impiego clinico degli inibitori della glicoproteina IIb/IIIa

Translated title of the contribution: Clinical usefulness of glycoprotein IIb/IIIa inhibitors

I. Simonetti, M. Gallopin, G. F. Gensini

Research output: Contribution to journalArticlepeer-review


Glycoprotein IIb/IIIa inhibitors are a new class of very powerful antiplatelet agents that act by inhibiting fibrinogen interplatelet bridges. Abciximab, tirofiban, lamifiban, and integrelin, all intravenous formulations, have been evaluated in phase II and phase III clinical trials. Although there seem to be relevant differences among drugs, their efficacy in treating acute ischemic syndromes and preventing acute complications of coronary angioplasty has been demonstrated. The major side effect has been an increase in bleeding complications. Future studies will be aimed at optimizing results and improving safety through more accurate assessment of optimal dosage and duration of infusion.

Translated title of the contributionClinical usefulness of glycoprotein IIb/IIIa inhibitors
Original languageItalian
Pages (from-to)163-168
Number of pages6
JournalAnnali Italiani di Medicina Interna
Issue number3
Publication statusPublished - 1998

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Clinical usefulness of glycoprotein IIb/IIIa inhibitors'. Together they form a unique fingerprint.

Cite this